Prurigo

Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™

Retrieved on: 
Wednesday, October 21, 2020
Prurigo nodularis, Prurigo

NEW HAVEN, Conn., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions, today, announced updates to their ongoing clinical trials of Haduvio.

Key Points: 
  • NEW HAVEN, Conn., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions, today, announced updates to their ongoing clinical trials of Haduvio.
  • We are pleased with the continued progress of our clinical development programs in these two severe conditions, said Jennifer L. Good, President and CEO of Trevi Therapeutics.
  • Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.
  • Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.

Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, September 9, 2020
Health, Clinical research, Food and Drug Administration, Articles, Prurigo nodularis, Drug discovery, Pharmaceutical industry, Prurigo, Clinical trial, Investigational New Drug

An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.

Key Points: 
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.
  • Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.
  • Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
  • Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Insights on the Worldwide Prurigo Nodularis Market to 2030 - US Hold the Highest Market Size - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 19, 2020
Health, Pharmaceutical, Prurigo nodularis, Prurigo, Market

The "Prurigo Nodularis (PN) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prurigo Nodularis (PN) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Prurigo nodularis (PN) market size from 2017 to 2030.
  • The Prurigo nodularis (PN) market report gives a thorough understanding of Prurigo nodularis (PN) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
  • The market size of Prurigo nodularis in the seven major markets is USD 659.29 Million in 2017.

Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, August 5, 2020
Health, Clinical research, Food and Drug Administration, Prurigo nodularis, Drug discovery, Pharmaceutical industry, Prurigo, Clinical trial, Investigational New Drug

An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.

Key Points: 
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.
  • Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
  • Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
  • Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis

Retrieved on: 
Monday, July 13, 2020
Clinical research, Health, Medical research, Design of experiments, Medicine, Prurigo nodularis, Prurigo, Clinical trial, Placebo-controlled study, Placebo

Based on the DMCs recommendation, the Company plans to increase the size of the trial to 360 subjects.

Key Points: 
  • Based on the DMCs recommendation, the Company plans to increase the size of the trial to 360 subjects.
  • Severe pruritus in prurigo nodularis is a very serious and difficult-to-treat condition.
  • The PRISM trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Haduvio for severe pruritus in patients with prurigo nodularis.
  • Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis (PN).

TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE

Retrieved on: 
Wednesday, April 8, 2020
Organ systems, Chemical compounds, Organic compounds, Parkinson's disease, Morphinans, Phenols, Tertiary alcohols, Ethers, Nalbuphine, Idiopathic pulmonary fibrosis, Prurigo nodularis, Prurigo

An archived replay of the webcast will also be available for 90 days on the Company's website following the conference.

Key Points: 
  • An archived replay of the webcast will also be available for 90 days on the Company's website following the conference.
  • Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
  • Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinsons disease.
  • Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Retrieved on: 
Thursday, February 20, 2020
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Infectious diseases, Genetics, Science, Clinical trials, Monoclonal antibodies, Prurigo nodularis, Medical specialties, Prurigo, Nemolizumab, Medicine, Clinical medicine, Nemolizumab, Galderma

Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31 that play a key role in the pathogenesis of PN.

Key Points: 
  • Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31 that play a key role in the pathogenesis of PN.
  • The Phase 2 study results indicate that nemolizumab may have a key role to play for patients with moderate to severe prurigo nodularis.
  • We are fully committed to test this drug further in Phase 3 studies and determined to bring solutions for patients suffering from prurigo nodularis.
  • Galderma is actively preparing for the initiation of a Phase 3 pivotal program with nemolizumab in adult patients with PN in 2020.

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

Retrieved on: 
Monday, January 13, 2020
Health, Drug discovery, Pharmaceutical industry, Clinical research, Pharmacology, Design of experiments, Prurigo nodularis, Clinical trial, Prurigo, Pre-clinical development

Kiniksas Breakthrough Therapy application was based on final data from an open-label Phase 2 clinical trial of rilonacept in a range of recurrent pericarditis populations.

Key Points: 
  • Kiniksas Breakthrough Therapy application was based on final data from an open-label Phase 2 clinical trial of rilonacept in a range of recurrent pericarditis populations.
  • Kiniksa expects top-line data from a Phase 2a clinical trial of KPL-716 in patients with prurigo nodularis in the first half of 2020.
  • Kiniksa is enrolling and dosing subjects in a single-ascending-dose Phase 1 clinical trial of KPL-404 in healthy volunteers.
  • Based on preclinical data in the context of Kiniksas portfolio, the company no longer plans to progress KPL-045 into clinical development.

Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis

Retrieved on: 
Monday, December 9, 2019
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, FDA, Medical devices, Clinical trials, Prurigo nodularis, Prurigo, the Breakthrough Therapy Designation, Nemolizumab, Galderma

Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.

Key Points: 
  • Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.
  • Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus.
  • We are very excited by the prospect of offering a treatment option to doctors, and their patients with prurigo nodularis, where currently there are no registered therapy options.
  • Galderma is now actively preparing for the initiation of a Phase 3 pivotal program with nemolizumab in adult patients with prurigo nodularis in 2020.

Trevi Therapeutics to Present at Stifel Healthcare Conference

Retrieved on: 
Wednesday, November 13, 2019
Organ systems, Chemical compounds, Organic compounds, Parkinson's disease, Morphinans, Phenols, Tertiary alcohols, Ethers, Nalbuphine, Idiopathic pulmonary fibrosis, Prurigo nodularis, Prurigo

An archived replay of the webcast will be available for 90 days on the Company's website following the conference.

Key Points: 
  • An archived replay of the webcast will be available for 90 days on the Company's website following the conference.
  • Trevi Therapeutics, Inc.is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
  • Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinsons disease.
  • Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.